We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Takeda and Lundbeck Petition FDA on Trintellix Labeling
Takeda and Lundbeck Petition FDA on Trintellix Labeling
Takeda and Lundbeck have requested that the FDA require all applicants for generics of their antidepressant, Trintellix (vortioxetine), to include information on the med’s association with sexual dysfunction.